Evidence map›Paper›PMID 36979684›Full record

ReviewBiomedicines2023

The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer.

Gabriela Bordeianu, Nina Filip, Andrei Cernomaz, Bogdan Veliceasa, Loredana Liliana Hurjui, Alin Constantin Pinzariu, Mihaela Pertea, Andreea Clim, Mihai Vasile Marinca, Ionela Lacramioara Serban

Full text readReview
In one paragraph

Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Role of Nanoformulations in the Treatment of Lung Cancer.Recent patents on nanotechnology · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriela BordeianuDepartment of Morpho-Functional Sciences (II), Discipline of Biochemistry, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Nina FilipDepartment of Morpho-Functional Sciences (II), Discipline of Biochemistry, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0003-0949-7538
Andrei CernomazIII-rd Medical Department, Discipline of Pneumology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Bogdan VeliceasaDepartment of Orthopedics and Traumatology, Surgical Science (II), Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-9941-3424
Loredana Liliana HurjuiDepartment of Morpho-Functional Sciences (II), Discipline of Physiology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0003-3803-9405
Alin Constantin PinzariuDepartment of Morpho-Functional Sciences (II), Discipline of Physiology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0001-5730-1662
Mihaela PerteaDepartment of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania.ORCID 0000-0002-5308-7192
Andreea ClimDepartment of Morpho-Functional Sciences (II), Discipline of Physiology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Mihai Vasile MarincaIII-rd Medical Department, Discipline of Oncology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-2193-3059
Ionela Lacramioara SerbanDepartment of Morpho-Functional Sciences (II), Discipline of Physiology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains a major public health problem both in terms of incidence and specific mortality despite recent developments in terms of prevention, such as smoking reduction policies and clinical management advances. Better lung cancer prognosis could be achieved by early and accurate diagnosis and improved therapeutic interventions. Nanotechnology is a dynamic and fast-developing field; various medical applications have been developed and deployed, and more exist as proofs of concepts or experimental models. We aim to summarize current knowledge relevant to the use of nanotechnology in lung cancer management. Starting from the chemical structure-based classification of nanoparticles, we identify and review various practical implementations roughly organized as diagnostic or therapeutic in scope, ranging from innovative contrast agents to targeted drug carriers. Available data are presented starting with standards of practice and moving to highly experimental methods and proofs of concept; particularities, advantages, limits and future directions are explored, focusing on the potential impact on lung cancer clinical prognosis.

Indexed as

drugslung cancernanomedicinenanoparticles

Identifiers

PMID36979684
PMCPMC10045176

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read13
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.